Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Morel

Showing results (431-440 of 444) with videos related to

Pageof 45
Sort By:
BMJ Open|October 10, 2019
Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trialSalma Shickh, Marc Clausen, Chloe Mighton, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 14, 2023
LHX2 haploinsufficiency causes a variable neurodevelopmental disorderCosima M Schmid, Anne Gregor, Gregory Costain, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 12, 2024
Opportunistic genomic screening has clinical utility: An interventional cohort studyChloe Mighton, Rita Kodida, Salma Shickh, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 17, 2025
Opportunistic screening for broad range of medically relevant secondary findings: Laboratory benefits and burdensChloe Mighton, Emma Reble, Jordan Sam, et al.
Journal of Medical Genetics|June 26, 2020
Exome and genome sequencing in adults with undiagnosed disease: a prospective cohort studySalma Shickh, Mariana Gutierrez Salazar, Kathleen-Rose Zakoor, et al.
BMJ Open|March 27, 2026
Understanding the impact of genomic secondary findings on clinical care and patient experience: a protocol for a prospective observational studyDaniel Assamad, Abigail Hansen, Katharine Fooks, et al.
Journal of Genetic Counseling|May 5, 2026
Understanding the decision of parents to opt-out of medically actionable secondary findings offered through genome sequencingAbigail Hansen, Stephanie Luca, Olivia Moran, et al.
NPJ Genomic Medicine|December 8, 2021
De novo variants in H3-3A and H3-3B are associated with neurodevelopmental delay, dysmorphic features, and structural brain abnormalitiesVolkan Okur, Zefu Chen, Liesbeth Vossaert, et al.
American Journal of Human Genetics|November 9, 2010
Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophreniaDaniel Moreno-De-Luca, , Jennifer G Mulle, et al.
American Journal of Human Genetics|July 22, 2020
De Novo Variants in the ATPase Module of MORC2 Cause a Neurodevelopmental Disorder with Growth Retardation and Variable Craniofacial DysmorphismMaria J Guillen Sacoto, Iva A Tchasovnikarova, Erin Torti, et al.
Pageof 45

Showing results (431-440 of 444) with videos related to

Sort By:
Pageof 45
BMJ Open|October 10, 2019
Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trialSalma Shickh, Marc Clausen, Chloe Mighton, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 14, 2023
LHX2 haploinsufficiency causes a variable neurodevelopmental disorderCosima M Schmid, Anne Gregor, Gregory Costain, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 12, 2024
Opportunistic genomic screening has clinical utility: An interventional cohort studyChloe Mighton, Rita Kodida, Salma Shickh, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 17, 2025
Opportunistic screening for broad range of medically relevant secondary findings: Laboratory benefits and burdensChloe Mighton, Emma Reble, Jordan Sam, et al.
Journal of Medical Genetics|June 26, 2020
Exome and genome sequencing in adults with undiagnosed disease: a prospective cohort studySalma Shickh, Mariana Gutierrez Salazar, Kathleen-Rose Zakoor, et al.
BMJ Open|March 27, 2026
Understanding the impact of genomic secondary findings on clinical care and patient experience: a protocol for a prospective observational studyDaniel Assamad, Abigail Hansen, Katharine Fooks, et al.
Journal of Genetic Counseling|May 5, 2026
Understanding the decision of parents to opt-out of medically actionable secondary findings offered through genome sequencingAbigail Hansen, Stephanie Luca, Olivia Moran, et al.
NPJ Genomic Medicine|December 8, 2021
De novo variants in H3-3A and H3-3B are associated with neurodevelopmental delay, dysmorphic features, and structural brain abnormalitiesVolkan Okur, Zefu Chen, Liesbeth Vossaert, et al.
American Journal of Human Genetics|November 9, 2010
Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophreniaDaniel Moreno-De-Luca, , Jennifer G Mulle, et al.
American Journal of Human Genetics|July 22, 2020
De Novo Variants in the ATPase Module of MORC2 Cause a Neurodevelopmental Disorder with Growth Retardation and Variable Craniofacial DysmorphismMaria J Guillen Sacoto, Iva A Tchasovnikarova, Erin Torti, et al.
Pageof 45